The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Immunogen Inc.

  • IMGN
  • NASDAQ
  • Consumer Products
  • Latest 11.23
  • Currency US$
  • Change 0.34
  • Percent Change 3.122 %
  • Volume 496,126
  • Fri Jul 11, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 10.91
  • Previous Close 10.89
  • High 11.26
  • Low 10.87
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High08/02 20.25
  • 52-week Low05/21 10.69
  • Beta 1.631
  • Market Cap 962.07M
  • EPS -0.79
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $57,990,000
  • Earnings $-66,750,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $164,070,000
  • Current Ratio 8.13

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $186,690,000
  • Liabilities $88,760,000
  • Liabilities-to-Equity Ratio 0.91

Price Ratios

  • Price to Sales 16.59
  • Price to Book 9.83
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Apr 25 $-0.29 Aug 1 $-0.36
Surprises Jan 31 -121.05% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 14, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

Related Securities
Symbol Type Latest % Chg

Officers

  • Stephen McCluski Chairman
  • Daniel M. Junius President;C.E.O and Director
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

830 WINTER ST
WALTHAM, MA
02451

Phone: (781)-895-0600
Fax: (781)-8950611

info@immunogen.com
www.immunogen.com

Ideas & Discussion

Live Discussion of IMGN on StockTwits